Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

deulorlatinib (TGRX-326)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Shenzhen TargetRx, Simcere

Drug class:

ALK inhibitor, ROS1 inhibitor

Related drugs:

‹

›

ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	TGRX-326 Sensitive: C2 – Inclusion Criteria TGRX-326 Sensitive : C2	TGRX-326 Sensitive: C2 – Inclusion Criteria TGRX-326 Sensitive : C2
ALK G1202R	Non Small Cell Lung Cancer	ALK G1202R	Non Small Cell Lung Cancer	TGRX-326 Sensitive: C3 – Early Trials TGRX-326 Sensitive : C3	TGRX-326 Sensitive: C3 – Early Trials TGRX-326 Sensitive : C3
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	TGRX-326 Sensitive: C3 – Early Trials TGRX-326 Sensitive : C3	TGRX-326 Sensitive: C3 – Early Trials TGRX-326 Sensitive : C3